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Abstract BACKGROUND: The expression of the HLA-G antigen from implantation toward 
term is crucial for the growth of a semiallogenic fetus as it shields this fetus from 
the maternal cytotoxic response. Little is known, however, about the potential role 
of soluble HLA-G isoforms during delivery. The initiation of labor is associated 
with a complex molecular response leading to a brief activation of the maternal 
immune system with an accompanying capacity to restrict this activation, and 
HLA-G seems to be an important factor in enabling the proper immune response 
at the maternal fetal interface.
METHODS: In our study the levels of soluble HLA-G concentration were evalu-
ated in the blood serum samples obtained from 47 pregnant women who either 
underwent cesarean sections or delivered vaginally. The patients were divided into 
three subgroups according to the progression of labor at the time of the cesarean 
or, in cases of vaginal delivery, according to the duration of the pregnancy. 
RESULTS: We have observed that the progression of labor is associated with a 
continuous increase in the sHLA-G plasma level. The sHLA-G levels were statisti-
cally significantly higher in the blood sera obtained from the women in advanced 
labor than from the women who were at the beginning of labor.
CONCLUSION: The changes in sHLA-G concentration levels observed during the 
stages of labor may indicate that this isoform participates in maintaining repro-
ductive tract homeostasis.
INTRODUCTION
HLA-G is a non-classical human leukocyte anti-
gen of Class Ib. It plays an important role in setting 
up and maintaining the immune tolerance that is 
achieved by the inhibition of immunocompetent 
cells [1]. As a result of an alternative splicing of a 
primary HLA-G transcript, seven isoforms of this 
antigen are generated. Four of them (G1-G4) are 
bound to a cell surface, while three others (G5-G7) 
that lack the exons for cytoplasmatic and trans-
membrane domain constitute the soluble isoforms 
[2,3]. The latter may be either secreted (HLA-G5) 
or proteolytically cleaved from the cell surface 
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(sHLA-G1). The function of the HLA-G molecule is 
firstly related to the fetal–maternal tolerance where its 
expression by cytotrophoblast prevents the fetus from 
attack by maternal natural killer (NK) cells [4]. As the 
non-classical HLA Class I molecule,HLA-G exerts its 
function by binding to inhibitory receptors-such as the 
leukocyte-inhibitory receptors LILRB1/ILT-2/CD85j, 
ILT-4/LILRB2/CD85d, and KIR2DL4 [5,6]-this inter-
action leads to the inhibition of the following processes: 
CD4+ T cell proliferation [5,7], the cytotoxic activity 
of CTL and NK cells [5,8,9], dendritic cell maturation 
[10], and the cell cycle progression of alloreactive T cells 
[11]. Furthermore, through the mechanism known as 
“trogocytosis”[12], HLA-G upregulates its own recep-
tors [13] and shifts the cytokine TH1/Th2 balance 
toward Th2 [14,15].
As with the membrane-bound HLA-G, the soluble 
isoforms exhibit the immunosuppressive activities [5] 
that are characteristic of HLA-G1 and the secreted 
HLA-G5 proteins. In addition, the soluble HLA-G iso-
forms (both shed HLA-G1 and HLA-G5) can induce 
Fas-dependent apoptosis of activated CD8+ T and NK 
cells [16,17] and can also inhibit angiogenesis by their 
interaction with the CD160/BY55 receptor [18]. The 
suppressive functions of soluble HLA-G isoforms may 
be seen not only at the local site of their expression but 
also – unlike their membrane-bound counterparts – at 
distant sites throughout the peripheral circulation. 
In pregnancy, it has been found that villous cytotro-
phoblast cells produce just one HLA-G isoform, 
HLA-G5 [19]. In contrast, the extravillous cytotropho-
blast that is close to the decidua, not only expresses the 
membrane HLA-G isoform, HLA-G1, but also possibly 
a second isoform, HLA-G2 [19,20]. Although HLA-G 
is produced by these cells throughout pregnancy, 
its expression is the highest in the first trimester and 
declines toward term. Soluble HLA-G isoform has been 
detected in the supernatant culture media from in vitro 
cultured embryos [21] and in maternal and cord blood 
[20] as well as in amniotic fluid. [22,23] 
The function of HLA-G and its soluble isoform in 
pregnancy has already been established in many studies. 
Expression of the HLA-G antigen, from implantation to 
term, is crucial for the growth of a semiallogenic fetus as 
it shields this fetus from the maternal cytotoxic response 
[19]. Disturbances in HLA-G expression are there-
fore thought to be associated with the development of 
various obstetric complications, such as, preeclampsia, 
placental abruption, or IUGR [24–26]. Little is known, 
however, about the potential role of HLA-G isoforms 
during delivery. The initiation of labor is associated not 
only with an increase in endocrine signals from the fetal 
adrenals, but also with a complex molecular response 
leading to a brief activation of the maternal immune 
system with an accompanying capacity to restrict this 
very activation [27–44], and HLA-G seems to be an 
important factor enabling the proper immune response 
at the maternal-fetal interface. In order to verify this 
hypothesis we have aimed in this study to measure the 
concentration level of the soluble HLA-G isoform with 
respect to the progression of labor at term.
2. MATERIALS AND METHODS
2.1 Patients
The blood serum samples evaluated in our study were 
obtained from 47 pregnant women who either under-
went cesarean sections or delivered vaginally. The 
women included in our study were selected from those 
who delivered in 2007 at the Department of Gynecol-
ogy, Obstetrics and Oncology of the Jagiellonian Uni-
versity, Krakow, Poland. The patients were divided into 
three subgroups either according to the progression 
of labor at the time of the cesarean or in cases of vagi-
nal delivery, according to the duration of pregnancy. 
The following groups were distinguished: Group One 
consisted of 24 women, 12 of whom underwent elec-
tive cesearean section without labor (i.e., with cervical 
external os closed ), and 12 women on whom cesarean 
sections were performed after the spontaneous begin-
ning of labor (i.e., whose cervical dilation was less than 
3 cm at the time of the cesarean). Group Two comprised 
7 women on whom cesarean sections were performed 
during advanced labor (i.e., whose cervical dilation 
was more than 3 cm at the time of the cesarean) and 9 
women who experienced spontaneous, uncomplicated 
vaginal delivery at term. Finally, Group Three con-
sisted of 7 women with preterm delivery (25–36 wks ). 
Preterm delivery at the time of diagnosis was accom-
panied by uncontrollable progressive cervical dilation 
and pathological findings in the CTG reading indicat-
ing fetal stress or the preterm rupture of membranes. 
The patients included in these subgroups delivered 
vaginally. The various indications for cesarean section 
were as follows: fetal distress syndrome, malpresenta-
tion, uterine myoma, previous cesarean delivery, and 
fetal heart defect. We have also used this division in our 
recent studies concerning the regulation of immune 
system activity during labor[27,28,35,45]. Patients with 
multiple pregnancies or existing complications of preg-
nancy (such as hypertension and diabetes mellitus) were 
excluded from this study, as were cases of fetal demise. 
Additionally, patients with intra-amniotic infection, as 
confirmed by histopathological examination of the fetal 
membranes and chorionic plate or other symptoms of 
intrauterine infections, were excluded from the study.
The patient’s consent was obtained in each case. 
Prior to the present study we also obtained the approval 
of the Jagiellonian University Ethical Committee for 
our research program (KBET/135/B/2007).
2.2. ELISA
The blood was collected in a serum collection tube 
prior to surgery in patients on whom cesarean sections 
were performed and, in cases of patients who delivered 
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vaginally, during the active phase of stage I of labor. A 
clot was allowed to form at room temperature for 30–60 
minutes. The tube was placed on ice for 30 minutes in 
order to contract the clot. The serum samples were then 
centrifuged at 3000 xg for 10 minutes at room tempera-
ture. The supernatants 1.0–2.0 ml were collected and 
stored at –80°C. The soluble human leukocyte antigen-G 
(sHLA-G) was determined using the sHLA-G sandwich 
ELISA kit (BioVendor-Exibo, Czech Republic). Stated 
briefly, the blood plasma samples were diluted twice 
and incubated for 1 hour in the 96-well microplate pre-
coated with the monoclonal anti-sHLA-G antibodies. 
Following incubation the wells were washed and filled 
with the monoclonal anti-human beta-2-microglobulin 
antibodies labeled with horseradish peroxidase. After 
an additional 1 hour of incubation, the wells were again 
washed and the color reaction was developed using 
tetramethyl benzidine (TMB) substrate. The absor-
bance values were measured at 450 nm on a microplate 
reader followed by calculation of the sHLA-G concen-
trations. Finally, the assay was calibrated using a set of 
sHLA-G standards provided by the producer of the kit.
2.3 Statistical analysis
The distribution of variables in the study groups of 
women checked with the use of the Shapiro-Wilk test 
showed that each of them was different from normal. 
The statistical significance between the groups was 
determined by the Kruskal-Wallis analysis of variance 
(ANOVA) test. The Mann-Whitney U test was then 
used as applicable.
RESULTS
3.1 Clinical comparison of analyzed groups of patients
Since the indications for performing a cesarean section 
vary, it would seem important to compare the param-
eters characterizing the course of pregnancy and labor 
in the groups of patients considered (Table 1).
We did not observe any statistically significant dif-
ferences in maternal clinical parameters among the 
groups examined. Since the examined group of patients 
included those with preterm delivery, the differences 
in clinical parameters such as gestational age, newborn 
mass, newborn length, and Apgar score are understood 
from a clinical point of view. This profile of clinical 
parameters characterizing the course of pregnancy 
enabled us to compare the respective sHLAG blood 
serum concentration levels in these groups.
3.1 Soluble SHLA-G levels in maternal bood serum with 
respect to the progression of labor
During labor at term, the blood serum sHLA-G con-
centration level significantly increases. The levels of 
sHLAG blood serum concentration in group I ranged 
from 0 to 26.6 U/ml (32% positive cases); in group II 
they ranged from 0 to 59.18 U/ml (75% positive cases), 
and in group III from 4.42 to 70.41 U/ml (all cases were 
positive). The highest level of sHLA-G concentration 
was observed in group III, that is, in the women with 
preterm delivery. The sHLA-G levels were statsitically 
significantly higher in the blood sera obtained from the 
women in advanced labor than in the sera from those 
women who were at the beginning of labor (Figure 1).
DISCUSSION
In the present study we have focused on the maternal 
sHLA-G plasma levels during the course of labor, and 
we have observed that the progression of labor is associ-
ated with a continuous increase in the sHLA-G plasma 
level. To our knowledge (based on a literature search in 
PubMed), this is the first investigation to concentrate 
on the sHLA-G level in patients who delivered by cesar-
ean at term according to the progression of labor at the 
time of the procedure.
During pregnancy, the HLA-G antigen is expressed 
in high levels by an extravillous trophoblast [19,46]. 
HLA-G protein is also present in maternal compart-
ment-decidua where its expression has been found to 
be dependent on hormones, mainly progesterone and 
certain cytokines [47]. The soluble isoform-sHLA-G is 
present in villous cytotrophoblast [48,49] and in mater-
nal and fetal circulation as well as in the amniotic fluid 
[19,22,23]. In the maternal plasma, the sHLA-G level 
is the highest during the first trimester of pregnancy 
Table 1. Clinical characteristic of patients 
Variables Group I(n=24)
Group II
(n=16)
Goup III
(n=7) p-value
Maternal age (median, IQR) 30 (7) 30 (6 ) 30.5 (8 ) 0.76
Parity (median, IQR) 2 (1.5) 1 (2) 2 (2) 0.33
Gestational age (median, IQR) 38 (2) 39 (2) 33 (6) <0.01
Newborn mass (median, IQR) 3145 (580) 3220 (560) 1920 (1100) 0.02
Newborn length (median, IQR) 53 (5) 54 (6) 47 (8) 0.01
Apgar score (median, IQR) 10 (1.5) 10 (0.0) 7 (2) <0.01
IQR – intraquartile range
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and then declines as term approaches. Similar changes 
in expression throughout pregnancy have been noted 
for a membrane-bound HLA-G isoform [22].
Expression of HLA-G at the feto-maternal interface 
is thought to protect the semiallogenic fetus from being 
rejected by acting as a barrier to maternal allo-immune 
competent cells. Membrane-bound HLA-G isoforms 
inhibit uterine natural killer (NK) cell function while 
soluble proteins modulate cytokine production by 
blood cells [14,15] and affect cytotoxic T lympho-
cytes by diverting their cycle to a programmed death 
[5,8,16,17]. In contrast, T helper lymphocytes are pro-
grammed into tolerant ones [12]. It has been suggested, 
based on the studies of embryo cultures, that HLA-G 
secretion is necessary for successful implantation [50]. 
Impaired expression of the HLA-G antigen by tropho-
blast cells as well as its soluble isoform is associated 
with obsteric complications. Decreased expression of 
HLA-G has been noted in recurrent pregnancy losses 
[51]. Moreover, compared to the levels found in normal 
pregnancy, the plasma levels of sHLA-G in cases of 
placental abruption and preeclampsia are low. [24–26, 
52,53]. Furthermore, a lower level early in the course of 
pregnancy may predict the occurence of preeclampsia 
later on [53]. In our study, the highest maternal blood 
serum sHLA-G concentration level was observed in 
patients with preterm labor. These results correlate well 
with the findings of Steinborn et al. who have reported 
that the level of sHLA-G in women with uncontrollable 
preterm labor as well as in the patients with HELLP 
syndrome is significantly increased [24,25]. The latter 
syndrome is also associated with a higher concentration 
level of sHLA-DR antigens in maternal circulation [54] 
than had previously been documented for the state of 
acute graft rejection after transplantation. The authors 
have therefore suggested that the patomechanism of 
these complications may resemble that of acute rejec-
tion where excessive allogenic reaction is key. 
Despite reports about how HLA-G isoforms function 
throughout pregnancy and in pregnancy-related disor-
ders, they have yet to be evaluated during the course 
of labor. In one of the studies, Steinborn et al. evalu-
ated pregnancies at term, and a significant difference 
between the mode of delivery and the level of sHLA-G 
in maternal circulation was not found. This would sug-
gest that the status of labor has no influence on the con-
tent of sHLA-G in the maternal plasma; however, the 
authors mentioned did not evalute sHLA-G according 
to the particular stage of labor [24].
So far it has been known that the beginning of partu-
rition is dependent upon signals from the fetal adrenal 
glands; more recently, a change in the pattern of cytokine 
concentration ( IL-6, Il-8) [33] as well as an increase in 
the cytotoxic activity of the immune cells has also been 
identified [30,31,35]. Our previous reports have shown 
that parturition is a dynamic process accompanied by 
particular immunological alterations; for example, 
alterations in the infiltration and activity of CD3+ and 
CD56+ cells in decidua, in immunoreactivity, and in the 
concentration of inhibitory proteins [27,28,32,35,42]. 
Figure 1. The analysis of the maternal blood serum concentration level according to the 
progression of labor at the time of the cesarean or, in cases of vaginal delivery, according 
to the duration of pregnancy. Group One consisted of both women who underwent 
elective cesearean sections without labor and women on whom cesarean sections were 
performed after the spontaneous beginning of labor. Group Two comprised both women 
who underwent cesarean sections during advanced labor and women who experienced 
spontaneous, uncomplicated vaginal delivery at term. Group Three consisted of women 
with preterm delivery.
71Neuroendocrinology Letters Vol. 30 No. 1 2009 • Article available online: http://node.nel.edu
Soluble HLA-G changes in maternal blood serum during the progression of labor
Steinborn et al. have observed that spontaneous labor at 
term is accompanied by a significantly elevated release 
of IL-6 from fetal monocytes that has not been found in 
cases of induced term or preterm delivery. It has been 
suggested that the fetal phagocyte activation was due to 
the presence of the maternal lymphocyte-T alloantigen 
stimulation that crosses the placental barrier at the end 
of pregnancy [29].
 The serum level of sHLA-G is higher in pregnant 
women than in non-pregnant women [22,23]. Soluble 
HLA-G concentration peaks in the first trimester and 
then decreases until term. As has been shown to be 
the case with the level of sHLA-G concentration in 
maternal blood during pregnancy, sHLA-G in amni-
otic fluid significantly decreases from the second tri-
mester until term [22]. Moreover, while a significant 
correlation between the sHLA-G concentration levels 
in maternal and fetal blood has been found, no such 
correlation between the levels of concentration in the 
maternal blood and amniotic fluid was observed [22]. 
The varied distribution of sHLA-G in body fluids 
during pregnancy as well as the changes in the protein 
concentration over the course of labor may suggest that 
the protein has a different origin. For this reason we can 
speculate that during delivery sHLA-G may be derived 
not only from trophoblasts, but also from the acti-
vated immune cells of both mother and fetus. Alegre 
et al. have discovered that maternal monocytes as well 
as DCs express sHLA-G in pregnancy. This suggests 
that the contribution of maternal APCs to the circu-
lating pool of HLA-G protein probably becomes more 
important as pregnancy advances [55. Furthermore, 
the secretion of sHLA-G was increased by IFN-gamma 
[55]; this finding agreed with previous reports where 
the role of cytokines in regulating such antigen expres-
sion has been documented [56–58]. Moreover, IL-10, 
which is also produced by cytotrophoblast cells, was 
seen to increase HLA-G expression. This cytokine plays 
an important role in maintaining the immune tolerance 
level crucial for a successful pregnancy. Additionally, it 
has been observed that the level of IL-10 was lower in 
women suffering from recurrent pregnancy losses [59]; 
this is similar to what has been reported for HLA-G 
[51] 
In our recent study, we have seen that this growth of 
maternal immune cell activity at the beginning of labor 
is associated with the subsequent growth of the expres-
sion of a decidual protein, such as RCAS1, and that its 
soluble form in maternal blood serum inhibits maternal 
cytotoxic cell activity [28,32,42,45,60–65]. In the pres-
ent study we have found that sHLA-G concentration 
rises with the progression of labor in a way comparable 
to the increase in the blood serum level of RCAS1 that 
takes place as labor advances. Moreover, the sHLA-G 
level was significantly higher in advanced labor than 
at the beginning of delivery. The changes in sHLA-G 
concentration levels observed during the various stages 
of labor may indicate that it participates in maintaining 
reproductive tract homeostasis.
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